Clinical Trials Directory

Trials / Completed

CompletedNCT02513433

Comparison of Levobupivacaine, Ropivacaine and Bupivacaine in Epidural Anaesthesia

Comparative Evaluation of Newer Congeners i.e. Levobupivacaine and Ropivacaine With Bupivacaine, in Lumbar Epidural Anaesthesia for Hip Surgeries

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
90 (actual)
Sponsor
Government Medical College, Haldwani · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

This study compares the clinical efficacy of newer local anaesthetic drugs Levobupivacaine and Ropivacaine with Bupivacaine in lumbar epidural anaesthesia for hip surgeries.

Detailed description

Some of the most common day care surgeries are hip surgeries, in which local anaesthetic agents can be used via epidural route for both intra-op and post-op analgesia. Among the drugs used nowadays are Lignocaine, Bupivacaine, Levobupivacaine and Ropivacaine.However Bupivacaine usage is not free from side effects. The claimed benefits of both Levobupivacaine and Ropivacaine are reduced cardiac toxicity on overdose and more specific effects on sensory rather than motor nerve fibres. Ropivacaine, an analog of Mepivacaine, is one of the long acting amide anaesthetic agent similar to Bupivacaine in chemical structure and anaesthetic function. It is a first enantiomer-specific compound, which has a reduced risk of cardio toxicity, neuro toxicity and rapid recovery of motor function. Levobupivacaine is the pure S (-)-enantiomer of Bupivacaine, and in recent year has emerged as a safer alternative for regional anaesthesia than its racemic parent.

Conditions

Interventions

TypeNameDescription
DRUGBupivacaineLocal anesthetic
DRUGLevobupivacaineLocal anesthetic
DRUGRopivacaineLocal anesthetic

Timeline

Start date
2012-12-01
Primary completion
2014-08-01
Completion
2014-09-01
First posted
2015-07-31
Last updated
2015-08-04

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT02513433. Inclusion in this directory is not an endorsement.